SCHEMBL879007

SCHEMBL879007

CC(C)c1ccc(F)c(OCC2CC2)c1

nearest known ligand 0.56

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
DUT P33316 17/20 0.47
PDE4B Q07343 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20204598 0.94 DUT (0.43) DUT
SCHEMBL25053730 0.94 DUT (0.43) DUT
SCHEMBL10289755 0.93 BCHE (0.43) DUT
SCHEMBL12630849 0.88 DUT (0.45) DUT
SCHEMBL1409345 0.88 DUT (0.45) DUT
SCHEMBL20361698 0.88 DUT (0.45) DUT
SCHEMBL11951596 0.88 ACACB (0.45) DUTPDE4B
SCHEMBL21325504 0.87 DUT (0.40) DUT
Hydrochloric Acid SCHEMBL20188271 0.87 DUT (0.45) DUT
Hydrochloric Acid SCHEMBL1408693 0.87 DUT (0.45) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11518746-B2 Nitrogen ring linked deoxyuridine triphosphatase inhibitors CV6 THERAPEUTICS (NI) LIMITED (GB) 2022-12-06 US disclosed
US-11198677-B2 Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2021-12-14 US disclosed
US-11168059-B2 Amino sulfonyl compounds CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-11-09 US disclosed
US-20210061767-A1 NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2021-03-04 US disclosed
US-20200325105-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-10-15 US disclosed
US-20200283394-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-09-10 US disclosed
US-20200270207-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CV6 THERAPEUTICS (NI) LIMITED (GB) 2020-08-27 US disclosed
US-10570100-B2 Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2020-02-25 US disclosed
US-20190330158-A1 AMINO SULFONYL COMPOUNDS CV6 THERAPEUTICS (NI) LIMITED (GB) 2019-10-31 US disclosed
US-20180194740-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE CV6 THERAPEUTICS (NI) LIMITED (GB) 2018-07-12 US disclosed
US-8304403-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2012-11-06 US disclosed
EP-1951690-B1 HETEROCYCLIC CETP INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-03-28 EP disclosed
EP-1954668-B9 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2012-03-21 EP disclosed
EP-1954668-B1 HOMO- AND HETEROCYCLIC COMPOUNDS SUITABLE AS CETP INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2011-09-28 EP disclosed
US-20100267669-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2010-10-21 US disclosed
US-7790770-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-09-07 US disclosed
US-20100041717-A1 N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2010-02-18 US disclosed
US-7652023-B2 Heterocyclic CETP inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2010-01-26 US disclosed
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 US disclosed
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2007-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041717-A1 N-((3-BENZYL)-2,2-(BIS-PHENYL)-PROPAN-1-AMINE DERIVATIVES AS CETP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASES CETP, APOB, CES1 DUT 2460/4885PDE4B 1191/4885
US-20180194740-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE DUT, DPYD, TYMP DUT 1/4885PDE4B 3233/4885
US-20200270207-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, TYMP, DPYD DUT 1/4885PDE4B 1710/4885
US-20210061767-A1 NITROGEN RING LINKED DEOXYURIDINE TRIPHOSPHATASE INHIBITORS DUT, DPYD, TYMP DUT 1/4885PDE4B 2599/4885
US-20070135631-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 DUT 887/4885PDE4B 2910/4885
US-20070135467-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 DUT 887/4885PDE4B 2910/4885
US-11168059-B2 Amino sulfonyl compounds DPYD, DNPEP, DUT DUT 3/4885PDE4B 3785/4885
US-20190330158-A1 AMINO SULFONYL COMPOUNDS DPYD, DNPEP, DUT DUT 3/4885PDE4B 3785/4885
US-11518746-B2 Nitrogen ring linked deoxyuridine triphosphatase inhibitors DUT, DPYD, TYMP DUT 1/4885PDE4B 2599/4885
US-11198677-B2 Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage DUT, DPYD, TYMP DUT 1/4885PDE4B 3233/4885
US-20200325105-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING AMINO SULFONYL LINKAGE DUT, DPYD, TYMP DUT 1/4885PDE4B 3233/4885
US-20100267669-A1 HETEROCYCLIC CETP INHIBITORS CETP, CES1, NPC1 DUT 887/4885PDE4B 2910/4885
US-10570100-B2 Deoxyuridine triphosphatase inhibitors containing amino sulfonyl linkage DUT, DPYD, TYMP DUT 1/4885PDE4B 3233/4885
US-20200283394-A1 DEOXYURIDINE TRIPHOSPHATASE INHIBITORS CONTAINING CYCLOPROPANO LINKAGE DPYD, DUT, TYMP DUT 2/4885PDE4B 2126/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.